Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

153h-index103.0kcitations2.8kworks5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(745), RNA modifications and cancer(490), Cancer Genomics and Diagnostics(414), Cancer Immunotherapy and Biomarkers(406), Lung Cancer Research Studies(238)

Publications2.8k total

Editor’s Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Cancer Discovery·2025Open Access
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer
Nature Cell Biology·2025· 1 cited
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer
Cancers·2025Open Access
Supplementary Figure 11 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplementary Figures and Tables from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplementary Figure 12 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2025Open Access
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence
Nature Communications·2025· 1 citedOpen Access
MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer
npj Precision Oncology·2025· 1 citedOpen Access
Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions
Cancer Cell·2025· 9 cited
PT1.07.01 IASLC Multidisciplinary Recommendations for Pathological Response Evaluation of Resected Lymph Nodes After Neoadjuvant Therapy in NSCLC
Journal of Thoracic Oncology·2025· 1 cited
page 1 of 141Next →

Frequent Co-authors

John V. Heymach(17), John D. Minna(14), Jing Wang(12), Lauren A. Byers(12), Lixia Diao(12), Fred R. Hirsch(8), Adi F. Gazdar(8), Ming‐Sound Tsao(8), William D. Travis(7), Keith M. Kerr(7), Edwin R. Parra(7), Lynette M. Sholl(7), J. Jack Lee(7), Junya Fujimoto(7), Don L. Gibbons(7), Andrew G. Nicholson(6), Yasushi Yatabe(6), Bonnie S. Glisson(6), Ferdinandos Skoulidis(6), Vassiliki A. Papadimitrakopoulou(6)